Testing is performed on Abbott’s ID NOW platform. Credit: Abbott.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Abbott’s new molecular point-of-care test to detect coronavirus (Covid-19).

The latest test runs on the company’s ID NOW platform and delivers positive results in five minutes and negative results within 13 minutes.

The ID NOW platform is a rapid, instrument-based, isothermal system used for the qualitative detection of infectious diseases.

Its isothermal nucleic acid amplification technology enables molecular results in minutes. Furthermore, it is small, lightweight and portable.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Abbott president and chief CEO Robert Ford said: “The Covid-19 pandemic will be fought on multiple fronts and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus.

“With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots.”

The company said it expects to scale up manufacturing to deliver 50,000 tests per day to meet the current demand for coronavirus tests. The ID NOW Covid-19 test will be launched next week.

It is the second EUA secured by Abbott for Covid-19 detection. The company received its first EUA for RealTime SARS-CoV-2 test from the US FDA this month.

RealTime SARS-CoV-2 is another molecular test for Covid-19 that runs on its m2000 RealTime System.

Combining both its Covid-19 tests, Abbott plans to deliver approximately five million tests per month to keep up with the diagnosis requirements.

Meanwhile, 143,025 confirmed coronavirus cases have been reported in the US. The death toll has reached over 2,509 in the country.